

Lillian L Siu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4071295/publications.pdf>

Version: 2024-02-01

260
papers

20,495
citations

10986

71
h-index

11939

134
g-index

265
all docs

265
docs citations

265
times ranked

26514
citing authors

#	ARTICLE	IF	CITATIONS
1	First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 57-70.	7.0	30
2	Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials. <i>Oncologist</i> , 2022, 27, e286-e293.	3.7	4
3	Early detection of treatment futility in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2022, 13, 61-72.	1.8	7
4	Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. <i>Science Advances</i> , 2022, 8, eabi8618.	10.3	61
5	Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. <i>Cancer Research Communications</i> , 2022, 2, 39-48.	1.7	4
6	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 51.	8.6	9
7	Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents. <i>Oncologist</i> , 2022, 27, 352-362.	3.7	6
8	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K β/δ , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	7.0	11
9	All is not lost: learning from 9p21 loss in cancer. <i>Trends in Immunology</i> , 2022, 43, 379-390.	6.8	12
10	A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. <i>Targeted Oncology</i> , 2022, 17, 271-281.	3.6	3
11	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3452-3463.	7.0	21
12	Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378.		4
13	Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics. <i>Cancer Treatment Reviews</i> , 2021, 92, 102125.	7.7	15
14	The Day After COVID-19 Time to Rethink Oncology Clinical Research. <i>JAMA Oncology</i> , 2021, 7, 23.	7.1	6
15	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa122.	2.9	12
16	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 980-988.	6.3	25
17	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 298-301.	10.7	11
18	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). <i>British Journal of Cancer</i> , 2021, 124, 1543-1551.	6.4	19

#	ARTICLE	IF	CITATIONS
19	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	46.4	208
20	The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , 2021, 11, 822-837.	9.4	32
21	Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. <i>Investigational New Drugs</i> , 2021, 39, 1587-1597.	2.6	15
22	Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4230-4244.	7.0	53
23	Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>PLoS ONE</i> , 2021, 16, e0253070.	2.5	17
24	Using real-world data to evaluate the effects of broadening eligibility criteria in oncology trials. <i>Cancer Cell</i> , 2021, 39, 750-752.	16.8	1
25	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 334-341.	2.3	9
26	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2117547.	5.9	20
27	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137.	12.8	63
28	Two-Target Quantitative PCR To Predict Library Composition for Shallow Shotgun Sequencing. <i>MSystems</i> , 2021, 6, e0055221.	3.8	5
29	HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2021, 27, 5857-5868.	7.0	38
30	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. , 2021, 9, e003476.		20
31	Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. <i>Cancer</i> , 2021, 127, 1620-1629.	4.1	56
32	Innovation and Advances in Precision Medicine in Head and Neck Cancer. , 2021, , 355-373.		2
33	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa115.	2.9	14
34	Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era. <i>European Journal of Cancer</i> , 2021, 158, 85-98.	2.8	16
35	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , 2021, 165, 94-102.	0.6	22
36	CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis. <i>Cell Genomics</i> , 2021, 1, 100033.	6.5	10

#	ARTICLE	IF	CITATIONS
37	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 469-472.	2.3	0
38	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100.	7.1	68
39	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , 2020, 144, 13-22.	0.6	30
40	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	4.1	26
41	Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. , 2020, 8, e001095.		27
42	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	7.0	6
43	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 5153-5161.	7.0	58
44	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nature Cancer</i> , 2020, 1, 873-881.	13.2	253
45	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
46	A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 1178-1188.	3.1	23
47	Phase 1 study of the immunotoxin LMB100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	4.1	31
48	Increasing operational and scientific efficiency in clinical trials. <i>British Journal of Cancer</i> , 2020, 123, 1207-1208.	6.4	11
49	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020, 38, 1774-1783.	2.6	13
50	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020, 16, 1235-1243.	2.4	36
51	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , 2020, 126, 3426-3437.	4.1	42
52	Circulating tumor DNA and liquid biopsy in oncology. <i>Nature Cancer</i> , 2020, 1, 276-290.	13.2	309
53	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , 2020, 395, 1078-1088.	13.7	302
54	Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , 2020, 9, 3015-3022.	2.8	21

#	ARTICLE	IF	CITATIONS
55	Molecular profiling for precision cancer therapies. <i>Genome Medicine</i> , 2020, 12, 8.	8.2	447
56	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020, 105, 104666.	1.5	8
57	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020, 9, 337.	1.6	6
58	Utilization of tumor genomics in clinical practice: an international survey among ASCO members. <i>Future Oncology</i> , 2019, 15, 2463-2470.	2.4	12
59	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019, 118, 112-120.	2.8	14
60	PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>Journal of Hepatology</i> , 2019, 70, e89.	3.7	4
61	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	2.9	4
62	Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 415.	2.8	114
63	Designing circulating tumor DNA-based interventional clinical trials in oncology. <i>Genome Medicine</i> , 2019, 11, 22.	8.2	24
64	TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 346-352.	2.5	29
65	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 655-663.	6.3	56
66	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)., 2019, 7, 72.		38
67	Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI-853520. <i>Targeted Oncology</i> , 2019, 14, 67-74.	3.6	7
68	Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. <i>Targeted Oncology</i> , 2019, 14, 43-55.	3.6	42
69	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349.	4.1	115
70	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , 2019, 24, e518-e525.	3.7	1
71	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019, 24, e146-e148.	3.7	23
72	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 118-128.	6.3	49

#	ARTICLE	IF	CITATIONS
73	Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. <i>Clinical Colorectal Cancer</i> , 2019, 18, e140-e149.	2.3	5
74	Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 261-273.	2.8	36
75	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1 ^{Low} /Negative Recurrent or Metastatic HNSCC. <i>JAMA Oncology</i> , 2019, 5, 195.	7.1	235
76	Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2542-2542.	1.6	5
77	Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. <i>Head and Neck</i> , 2018, 40, 2029-2042.	2.0	16
78	A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 1016-1025.	2.6	34
79	Rational design and identification of immuno-oncology drug combinations. <i>European Journal of Cancer</i> , 2018, 95, 38-51.	2.8	9
80	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018, 17, 73-79.	2.3	17
81	Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. <i>International Journal of Cancer</i> , 2018, 142, 57-65.	5.1	23
82	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168.	2.5	27
83	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 167-171.	2.5	14
84	Fcγ receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. <i>Cancer Medicine</i> , 2018, 7, 5478-5487.	2.8	19
85	Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , 2018, 11, 65.	1.5	16
86	Precision Medicine in Head and Neck Cancer: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491877958.	1.3	18
87	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 71-79.	2.2	26
88	Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , 2018, 9, 22559-22570.	1.8	20
89	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. <i>Gynecologic Oncology</i> , 2017, 144, 486-490.	1.4	47
90	Giant Prolactinoma Presenting As a Base of Skull Tumor With Nasopharyngeal Extension: A Potential Diagnostic Pitfall in Neuroendocrine Lesions of the Base of Skull. <i>Head and Neck Pathology</i> , 2017, 11, 537-540.	2.6	2

#	ARTICLE	IF	CITATIONS
91	Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball. <i>Cell</i> , 2017, 168, 575-578.	28.9	13
92	Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. <i>Clinical Cancer Research</i> , 2017, 23, 4020-4026.	7.0	14
93	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , 2017, 123, 1409-1415.	4.1	9
94	Sharing Clinical and Genomic Data on Cancer – The Need for Global Solutions. <i>New England Journal of Medicine</i> , 2017, 376, 2006-2009.	27.0	35
95	The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 39.	3.0	9
96	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 220.	7.1	64
97	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. <i>Targeted Oncology</i> , 2017, 12, 775-785.	3.6	64
98	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. <i>Clinical Cancer Research</i> , 2017, 23, 4950-4958.	7.0	46
99	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. <i>Cancer</i> , 2017, 123, 4147-4157.	4.1	70
100	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 1606-1621.	1.6	112
101	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , 2017, 8, 32918-32929.	1.8	46
102	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , 2017, 8, 84659-84670.	1.8	13
103	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , 2016, 34, 575-583.	2.6	9
104	Facilitating a culture of responsible and effective sharing of cancer genome data. <i>Nature Medicine</i> , 2016, 22, 464-471.	30.7	83
105	A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. <i>Investigational New Drugs</i> , 2016, 34, 450-457.	2.6	36
106	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016, 67, 174-182.	2.8	75
107	Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001016.	1.2	5
108	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. <i>Oral Oncology</i> , 2016, 59, 43-49.	1.5	16

#	ARTICLE	IF	CITATIONS
109	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 994-1002.	0.8	3
110	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , 2016, 8, 115.	8.2	64
111	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	8.2	211
112	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (P)C008/NCIâ™9041). <i>Investigational New Drugs</i> , 2016, 34, 104-111.	2.6	17
113	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 858-867.	7.0	28
114	A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-“Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1348-1355.	7.0	48
115	PD-L1 Testing in Cancer. <i>JAMA Oncology</i> , 2016, 2, 15.	7.1	116
116	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , 2016, 18, 128-136.	2.4	83
117	Cancer genomics. <i>Current Opinion in Oncology</i> , 2015, 27, 250-257.	2.4	14
118	Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT). <i>Investigational New Drugs</i> , 2015, 33, 895-900.	2.6	11
119	Cancer patientsâ€™ acceptability of incorporating an epidemiology questionnaire within a clinical trial. <i>Clinical Trials</i> , 2015, 12, 237-245.	1.6	2
120	A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. <i>Clinical Cancer Research</i> , 2015, 21, 68-76.	7.0	65
121	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , 2015, 9, 997-1007.	4.6	81
122	A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2793-2802.	1.3	33
123	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus-Related Oropharyngeal Carcinomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 836-845.	1.6	345
124	Toward understanding and exploiting tumor heterogeneity. <i>Nature Medicine</i> , 2015, 21, 846-853.	30.7	604
125	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	3.0	128
126	A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. <i>Cancer</i> , 2015, 121, 1785-1792.	4.1	51

#	ARTICLE	IF	CITATIONS
127	Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 1570-1579.	2.8	62
128	A multicenter phase 1 study of \hat{I}^3 -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 169-176.	2.6	32
129	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015, 33, 652-663.	2.6	35
130	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , 2015, 20, 653-659.	3.7	21
131	All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. <i>Cancer Discovery</i> , 2015, 5, 1133-1136.	9.4	45
132	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1100-1107.	2.6	121
133	Next-Generation Sequencing to Guide Clinical Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4536-4544.	7.0	59
134	Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3372-3374.	1.6	12
135	Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e98557.	2.5	11
136	Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 763-765.	1.4	11
137	A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. <i>Investigational New Drugs</i> , 2014, 32, 1269-1277.	2.6	45
138	Genomic testing in cancer: Patient knowledge, attitudes, and expectations. <i>Cancer</i> , 2014, 120, 3066-3073.	4.1	72
139	Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. <i>European Journal of Human Genetics</i> , 2014, 22, 391-395.	2.8	98
140	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 1.	17.0	156
141	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , 2014, 32, 243-249.	2.6	70
142	Promising SINEs for Embargoing Nuclearâ€™Cytoplasmic Export as an Anticancer Strategy. <i>Cancer Discovery</i> , 2014, 4, 527-537.	9.4	89
143	Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 670-681.	2.6	165
144	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014, 32, 1005-1016.	2.6	29

#	ARTICLE	IF	CITATIONS
145	Quality of life in patients with KRAS wild-type colorectal cancer. <i>Cancer</i> , 2014, 120, 181-189.	4.1	18
146	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. <i>European Journal of Cancer</i> , 2014, 50, 2050-2056.	2.8	63
147	Phase 1 Trial Design: Is 3 + 3 the Best?. <i>Cancer Control</i> , 2014, 21, 200-208.	1.8	59
148	A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3057-3057.	1.6	1
149	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1182-1191.	2.6	50
150	Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 4260-4267.	1.6	83
151	Epidermal Growth Factor Receptor Targeting in Head and Neck Cancer: Have We Been Just Skimming the Surface?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1381-1383.	1.6	36
152	Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1547-1555.	5.1	76
153	Clinical genomics information management software linking cancer genome sequence and clinical decisions. <i>Genomics</i> , 2013, 102, 140-147.	2.9	14
154	Tumour heterogeneity in the clinic. <i>Nature</i> , 2013, 501, 355-364.	27.8	993
155	Designing Transformative Clinical Trials in the Cancer Genome Era. <i>Journal of Clinical Oncology</i> , 2013, 31, 1834-1841.	1.6	166
156	Deintensification Candidate Subgroups in Human Papillomavirus-Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-550.	1.6	551
157	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type KRAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2477-2484.	1.6	122
158	Selecting the Best Drugs for Phase I Clinical Development and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 469-473.	3.8	1
159	Less Than Ideal: How Oncologists Practice With Limited Drug Access. <i>Journal of Oncology Practice</i> , 2012, 8, 190-195.	2.5	11
160	A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 255-260.	1.3	45
161	The Utility of Hedgehog Signaling Pathway Inhibition for Cancer. <i>Oncologist</i> , 2012, 17, 1090-1099.	3.7	44
162	Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway. <i>Journal of Clinical Oncology</i> , 2012, 30, 2919-2928.	1.6	188

#	ARTICLE	IF	CITATIONS
163	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , 2012, 103, 49-56.	0.6	167
164	Ocular Toxicity of Targeted Therapies. <i>Journal of Clinical Oncology</i> , 2012, 30, 3277-3286.	1.6	117
165	A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3082-3082.	1.6	3
166	Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3504-3504.	1.6	5
167	A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS5600-TPS5600.	1.6	2
168	Important Early Advances in Squamous Cell Carcinoma of the Head and Neck. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 373-376.	3.8	1
169	Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3572-3572.	1.6	0
170	Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3027-3027.	1.6	1
171	Brivanib alaninate for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 577-586.	4.1	39
172	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2011, 98, 15-22.	0.6	102
173	Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , 2011, 29, 934-943.	1.6	280
174	A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2011, 29, 996-1003.	2.6	24
175	Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?. <i>BMC Cancer</i> , 2011, 11, 426.	2.6	25
176	Significance of Dysregulated Metadherin and MicroRNA-375 in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7539-7550.	7.0	82
177	Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas. <i>Clinical Cancer Research</i> , 2011, 17, 1582-1590.	7.0	95
178	Targeting the Hedgehog Pathway in Cancer: Can the Spines Be Smoothened?. <i>Clinical Cancer Research</i> , 2011, 17, 2071-2073.	7.0	11
179	The Contents and Readability of Informed Consent Forms for Oncology Clinical Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 387-392.	1.3	21
180	Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1401-1407.	1.6	52

#	ARTICLE	IF	CITATIONS
181	Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2010, 16, 1726-1736.	7.0	152
182	Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1188-1198.	6.3	298
183	Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma. <i>Clinical Cancer Research</i> , 2010, 16, 4038-4045.	7.0	95
184	Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 751-760.	4.1	20
185	Magnetic resonance imaging of nasopharyngeal carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 365-375.	2.4	20
186	Reply to D.J. Stewart. <i>Journal of Clinical Oncology</i> , 2010, 28, e651-e651.	1.6	2
187	Molecular targeted therapies in all histologies of head and neck cancers: an update. <i>Current Opinion in Oncology</i> , 2010, 22, 212-220.	2.4	24
188	Randomized Phase II Trials: Inevitable or Inadvisable?. <i>Journal of Clinical Oncology</i> , 2010, 28, 2641-2647.	1.6	78
189	Hepatic steatosis secondary to capecitabine: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 227.	0.8	9
190	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 3177-3183.	7.0	103
191	Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5965-5971.	1.6	23
192	Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 6213-6221.	1.6	289
193	Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. <i>Investigational New Drugs</i> , 2009, 27, 586-594.	2.6	59
194	Dose Escalation Methods in Phase I Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2009, 101, 708-720.	6.3	678
195	Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 339-349.	5.9	6
196	Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2008, 26, 257-264.	2.6	74
197	Adherence to Surveillance Guidelines After Curative Resection for Stage II/III Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 191-196.	2.3	24
198	Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. <i>Drug Resistance Updates</i> , 2008, 11, 99-109.	14.4	29

#	ARTICLE	IF	CITATIONS
199	Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents. <i>Journal of Clinical Oncology</i> , 2008, 26, 1324-1330.	1.6	19
200	Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 1940-1947.	1.6	116
201	Improving the Quality of Abstract Reporting for Phase I Cancer Trials. <i>Clinical Cancer Research</i> , 2008, 14, 1782-1787.	7.0	10
202	A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 833-839.	7.0	114
203	A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 3450-3455.	7.0	180
204	Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay. <i>Clinical Cancer Research</i> , 2008, 14, 3441-3449.	7.0	88
205	Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1247-1254.	4.1	20
206	Neuroendocrine Tumors of the Gastrointestinal Tract. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 64-70.	1.3	50
207	Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. <i>Current Opinion in Oncology</i> , 2008, 20, 256-263.	2.4	50
208	Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. <i>Journal of Clinical Oncology</i> , 2007, 25, 3978-3984.	1.6	240
209	Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. <i>Journal of Clinical Oncology</i> , 2007, 25, 2184-2190.	1.6	92
210	Clinical Trials in the Elderly – A Concept Comes of Age. <i>New England Journal of Medicine</i> , 2007, 356, 1575-1576.	27.0	65
211	Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval. <i>Journal of Clinical Oncology</i> , 2007, 25, 3362-3371.	1.6	198
212	Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3766-3773.	1.6	230
213	Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2178-2183.	1.6	138
214	Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 4849-4857.	7.0	90
215	The Influence of Mentorship on Research Productivity in Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 549-555.	1.3	7
216	A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. <i>Investigational New Drugs</i> , 2007, 25, 217-225.	2.6	25

#	ARTICLE	IF	CITATIONS
217	The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. <i>Supportive Care in Cancer</i> , 2007, 15, 829-840.	2.2	31
218	Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination. <i>Clinical Cancer Research</i> , 2006, 12, 2141-2149.	7.0	33
219	Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. <i>Anti-Cancer Drugs</i> , 2006, 17, 81-87.	1.4	3
220	Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. <i>BMC Cancer</i> , 2006, 6, 263.	2.6	53
221	Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. <i>International Journal of Cancer</i> , 2006, 119, 2467-2475.	5.1	87
222	Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents. <i>Journal of Clinical Oncology</i> , 2006, 24, 4801-4807.	1.6	95
223	Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 144-151.	7.0	182
224	Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 225-31.	1.3	100
225	A Multicenter Phase II Study of Adjuvant Irinotecan Following Resection of Colorectal Hepatic Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 547-554.	1.3	14
226	Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 814, 143-147.	2.3	40
227	Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 154-160.	2.3	37
228	Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2005, 23, 455-465.	2.6	4
229	Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada. <i>Journal of Clinical Oncology</i> , 2005, 23, 3802-3810.	1.6	105
230	Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 6966-6975.	1.6	420
231	Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 2332-2338.	1.6	297
232	A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5526-5533.	7.0	99
233	Raf kinase as a target for anticancer therapeutics. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 677-685.	4.1	235
234	Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens. <i>Journal of Clinical Oncology</i> , 2005, 23, 6982-6991.	1.6	137

#	ARTICLE	IF	CITATIONS
235	Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions. <i>Current Pharmaceutical Design</i> , 2005, 11, 265-272.	1.9	24
236	Phase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea. <i>Journal of Clinical Oncology</i> , 2004, 22, 4410-4417.	1.6	70
237	Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2004, 22, 77-85.	1.6	753
238	Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. <i>Investigational New Drugs</i> , 2003, 21, 85-97.	2.6	81
239	Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. <i>Supportive Care in Cancer</i> , 2003, 11, 41-47.	2.2	42
240	Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?. <i>Journal of Clinical Oncology</i> , 2003, 21, 1618-1623.	1.6	292
241	Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents. <i>Journal of Clinical Oncology</i> , 2003, 21, 2760-2776.	1.6	131
242	Are Older Cancer Patients Being Referred to Oncologists? A Mail Questionnaire of Ontario Primary Care Practitioners to Evaluate Their Referral Patterns. <i>Journal of Clinical Oncology</i> , 2003, 21, 4627-4635.	1.6	44
243	The statins as anticancer agents. <i>Clinical Cancer Research</i> , 2003, 9, 10-9.	7.0	579
244	Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 2478-86.	7.0	102
245	Phase I and Pharmacokinetic Study of Novel I-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days. <i>Journal of Clinical Oncology</i> , 2002, 20, 2567-2574.	1.6	21
246	Rationale for Ras and Raf-kinase as a Target for Cancer Therapeutics. <i>Current Pharmaceutical Design</i> , 2002, 8, 2231-2242.	1.9	37
247	Troxacitabine, an I-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2002, 20, 96-109.	1.6	30
248	A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2002, 8, 2142-8.	7.0	90
249	A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. <i>Clinical Cancer Research</i> , 2002, 8, 2157-66.	7.0	22
250	Impact of the Media and the Internet on Oncology: Survey of Cancer Patients and Oncologists in Canada. <i>Journal of Clinical Oncology</i> , 2001, 19, 4291-4297.	1.6	229
251	Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2001, 19, 3267-3279.	1.6	981
252	Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 3677-3689.	1.6	30

#	ARTICLE	IF	CITATIONS
253	Phase I and Pharmacokinetic Study of the Differentiating Agent Vesnarinone in Combination With Gemcitabine in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3974-3985.	1.6	14
254	Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 4086-4097.	1.6	48
255	Telomerase: Therapeutic Potential in Cancer. <i>Cancer Investigation</i> , 2000, 18, 269-277.	1.3	15
256	A phase II study of temozolomide in advanced untreated pancreatic cancer. <i>Investigational New Drugs</i> , 1998, 16, 77-79.	2.6	24
257	Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. <i>Investigational New Drugs</i> , 1998, 16, 113-119.	2.6	21
258	Use of mesna to prevent ifosfamide-induced urotoxicity. <i>Supportive Care in Cancer</i> , 1998, 6, 144-154.	2.2	40
259	A Risk-Benefit Assessment of Irinotecan in Solid Tumours. <i>Drug Safety</i> , 1998, 18, 395-417.	3.2	11
260	Vinblastine and erythromycin: an unrecognized serious drug interaction. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 188-190.	2.3	33